Biomol Ther.  2015 Jan;23(1):71-76. 10.4062/biomolther.2014.042.

Ciglitazone, a Peroxisome Proliferator-Activated Receptor Gamma Ligand, Inhibits Proliferation and Differentiation of Th17 Cells

Affiliations
  • 1Division of Applied Life Science, Gyeongsang National University, Jinju 660-701, Republic of Korea. kdkim88@gnu.ac.kr
  • 2BK21 Plus, Gyeongsang National University, Jinju 660-701, Republic of Korea.
  • 3PMBBRC, Gyeongsang National University, Jinju 660-701, Republic of Korea.
  • 4College of Veterinary Medicine, Gyeongsang National University, Jinju 660-701, Republic of Korea.

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) was identified as a cell-intrinsic regulator of Th17 cell differentiation. Th17 cells have been associated with several autoimmune diseases, including experimental autoimmune encephalomyelitis (EAE), inflammatory bowel disease (IBD), and collagen-induced arthritis. In this study, we confirmed PPARgamma-mediated inhibition of Th17 cell differentiation and cytokine production at an early stage. Treatment with ciglitazone, a PPARgamma ligand, reduced both IL-1beta-mediated enhancement of Th17 differentiation and activation of Th17 cells after polarization. For Th17 cell differentiation, we found that ciglitazone-treated cells had a relatively low proliferative activity and produced a lower amount of cytokines, regardless of the presence of IL-1beta. The inhibitory activity of ciglitazone might be due to decrease of CCNB1 expression, which regulates the cell cycle in T cells. Hence, we postulate that a pharmaceutical PPARgamma activator might be a potent candidate for treatment of Th17-mediated autoimmune disease patients.

Keyword

Th17 cell; IL-17; PPARgamma; CCNB1; Cell proliferation

MeSH Terms

Arthritis, Experimental
Autoimmune Diseases
Cell Cycle
Cell Proliferation
Cytokines
Encephalomyelitis, Autoimmune, Experimental
Humans
Inflammatory Bowel Diseases
Interleukin-17
PPAR gamma*
T-Lymphocytes
Th17 Cells*
Cytokines
Interleukin-17
PPAR gamma
Full Text Links
  • BT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr